⌕
Jazz Pharmaceuticals · JAZZ · Nasdaq
Tenet 47 · Mixed
Compare
$240.71+0.39%At closeTenet 47 · Mixed
$240.71+0.94 (+0.39%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Jazz Pharmaceuticals (JAZZ) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 17, 2026 · 10:53 ET
Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

● Defense WorldNov 15, 2026 · 09:56 ETEARNINGS EXPECTED BY FEB 16
Allspring Global Investments Holdings LLC Acquires 42,827 Shares of Jazz Pharmaceuticals PLC $JAZZ

Allspring Global Investments Holdings LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 1,326.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm o…

● Zacks Investment ResearchNov 9, 2026 · 10:16 ET
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.…

● Defense WorldNov 5, 2026 · 04:29 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Th…

● PRNewsWireNov 3, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healt…

● Zacks Investment ResearchNov 3, 2026 · 12:16 ETEARNINGS EXPECTED BY FEB 16
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View

Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.…

● Schaeffers ResearchNov 3, 2026 · 11:36 ET
4 Biotech Stocks Seeing Unusual Options Volume Today

Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pha…

● Seeking AlphaNov 2, 2026 · 21:58 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript

Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 2, 2026 · 20:14 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals Q3 Earnings Call Highlights

Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset pr…

● Zacks Investment ResearchNov 2, 2026 · 19:31 ETEARNINGS EXPECTED BY FEB 16
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the y…

● Zacks Investment ResearchNov 2, 2026 · 18:25 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates

Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $3.88 per share versus the Zacks Consensus Estimate of a loss of $4.09. This compares to earnings of $8.13 per share a year ago.…

● PRNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results

– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY wi…

● PRNewsWireNov 2, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026

Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Na…

● The Motley FoolOct 27, 2026 · 16:09 ETEARNINGS EXPECTED BY FEB 16
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.…

● Zacks Investment ResearchOct 26, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 16
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● PRNewsWireOct 23, 2026 · 10:15 ETEARNINGS EXPECTED BY FEB 16
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy d…

● Defense WorldOct 20, 2026 · 03:31 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLC

CWA Asset Management Group LLC lifted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 24.3% during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exc…

● PRNewsWireOct 19, 2026 · 16:15 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial mar…

● Zacks Investment ResearchOct 16, 2026 · 10:20 ETEARNINGS EXPECTED BY FEB 16
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.…

● Seeking AlphaOct 15, 2026 · 08:43 ETEARNINGS EXPECTED BY FEB 16
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gro…

● Zacks Investment ResearchOct 6, 2026 · 10:41 ET
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

● Defense WorldOct 5, 2026 · 10:14 ETEARNINGS EXPECTED BY FEB 16
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on …

● Defense WorldSep 21, 2026 · 06:03 ET
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potentia…

● Defense WorldSep 21, 2026 · 06:03 ET
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Glob…

● PRNewsWireSep 15, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment optio…

● PRNewsWireSep 2, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Heal…

● PRNewsWireAug 31, 2026 · 06:00 ETEARNINGS EXPECTED BY FEB 16
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ra…

● PRNewsWireAug 27, 2026 · 00:30 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "n…

● PRNewsWireAug 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subjec…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just JAZZ · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.